What is ASND's market cap?

$16.46B, based on the Nov 3 close of $250.17.

Does Ascendis Pharma A/S Ordinary Share pay a dividend?

No regular cash dividend has been paid in the last year.

How much of ASND is sold short?

3.1M shares, 6.1% of float, as of Oct 15, 2026.

NASDAQ · ASND

Ascendis Pharma A/S Ordinary Share (ASND)

$250.17+0.48%

Close Nov 3, 2026 · split-adjusted

Oct 28, 2026$248.17▲ 22.11% in range

Oct 27, 2025Low $196.01 · High $277.18Oct 28, 2026

What changed · written from our data

As of Nov 3, 2026

Ascendis Pharma A/S Ordinary Share closed at $250.17 on Nov 3, up 0.48%, 9.7% below its 52-week closing high. Volume of 619.8K shares was 0.91× its 20-day average (close to normal).

Split-adjusted performance: +9.7% over one month, +11.0% over six months, +24.1% over one year.

In the quarter ended Jun 30, 2019, revenue was $157K, down 98.3% from a year earlier, with a net margin of -26170.1%.

Short interest was 3.1M shares at the Oct 15 settlement, down 10.1% from the prior report (6.1% of float, 4.2 days to cover).

Market cap$16.46B65.8M shares

Revenue · quarter$157.0K−98.3% YoY

Diluted EPS$-0.07—

P/E · TTM—

Net margin-26,170.1%Gross 100.0%

Dividend yieldNone

52-week range196.01 – 277.18−9.7% from high

Volume619.8K0.91× 20-day avg

Volatility · 60d37.0%Annualised

Short % of float6.1%4.2 days to cover

Net cash$133.4MCash $133.4M

Next earnings—Not scheduled

Split-adjusted performance

1W +1.8%1M +9.7%3M +2.4%6M +11.0%YTD +17.3%1Y +24.1%3Y +183.4%5Y +79.0%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within industry

Not enough peers to rank

6-month momentum—

Revenue growth—

Net margin—

Value (low P/E)—

Size—

Short interest

Details →

Shares short3.1M−10.1% vs prior

Days to cover4.2Settled Oct 15

% of float6.1%

Short vol. 10d59.3%of daily volume

News about Ascendis Pharma A/S Ordinary Share

All news →

Ascendis Announces Planned $400 Million Share Repurchase ProgramGlobeNewswire Inc. · Sep 14, 2026▲ Positive Why Is Ascendis Pharma Stock Gaining Friday?Benzinga · Jun 12, 2026▲ Positive Ascendis to Showcase Advances in Treatment of Rare Endocrine Diseases at ENDO 2026GlobeNewswire Inc. · Jun 8, 2026▲ Positive Ascendis Pharma to List Ordinary Shares Directly on NasdaqGlobeNewswire Inc. · Apr 8, 2026▲ Positive FDA Approves Once-Weekly YUVIWEL® (navepegritide) for Children with Achondroplasia Aged 2 Years and OlderGlobeNewswire Inc. · Feb 27, 2026▲ Positive

Quick answers

What does Ascendis Pharma A/S Ordinary Share do?: Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology, which includes TransCon PTH, TransCon CNP, and others.
What is ASND's market cap?: $16.46B, based on the Nov 3 close of $250.17.
Does Ascendis Pharma A/S Ordinary Share pay a dividend?: No regular cash dividend has been paid in the last year.
How much of ASND is sold short?: 3.1M shares, 6.1% of float, as of Oct 15, 2026.

About Ascendis Pharma A/S Ordinary Share

Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology, which includes TransCon PTH, TransCon CNP, and others. It operates in the United States, Europe, and the rest of the world and derives the majority of its revenue from the United States.

1,189 employeesListed Apr 20, 2026ascendispharma.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology